CBS9106

CBS9106 is a novel small molecule reversible inhibitor of Exportin-1 (XPO1), clinically validated target, to be administered orally.

Stemline Therapeutics, Inc., our global partner, is carrying on Phase 1 clinical trial in solid tumor.
The development code for CBS9106 is SL-801 by Stemline.

For more info on CBS9106/SL-801 please visit Stemline website.

Pipeline

CBP501

CBS9106